Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, ...

A type of bacteria dubbed “Conan the Bacterium” can withstand radiation thousands of times stronger than what can kill a ...

A type of bacteria dubbed “Conan the Bacterium” can withstand radiation thousands of times stronger than what can kill a ...

The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Retinol is the gold-standard ingredient that has been around for decades. It's one of the few products that comes with ...

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...